Core Viewpoint - Shandong Anhua Biological Pharmaceutical Co., Ltd. has announced a new company charter as part of its transition from a private to a public company on the New Third Board, indicating its successful completion of the listing review process [1][3]. Group 1: Company Overview - Anhua Biological, established in 2010, focuses on the research and production of bioactive substances, raw materials, medical aesthetics, and functional skincare products, holding 44 domestic and international patents [5][12]. - The company has developed proprietary technologies such as ProEnzy® for ultra-low molecular weight hyaluronic acid and Waterble® for microbial fermentation [5]. Group 2: Financial Performance - Revenue figures for Anhua Biological from 2022 to May 2024 show an increase from 78.80 million yuan to 98.09 million yuan, but net profit has declined from 17.02 million yuan to a loss of 1.58 million yuan [8][9]. - The revenue breakdown indicates a gradual decrease in the proportion of income from raw materials, with a shift towards functional skincare and medical terminal products [10][12]. Group 3: Market Position and Strategy - Anhua Biological maintains key partnerships with leading cosmetic companies like Proya, with significant revenue contributions from these collaborations [9][12]. - The company aims to leverage its new public status to enhance market influence and pursue further growth opportunities, potentially targeting higher-tier capital markets in the future [17]. Group 4: Historical Context - This is not Anhua Biological's first attempt at public listing; it previously listed on the New Third Board in 2015 but withdrew in 2021 due to unfavorable trading conditions [13][15]. - The company has undergone capital restructuring and partnerships to strengthen its market position, indicating a strategic pivot towards public financing for future expansion [16].